Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...
Patients with Prader-Willi syndrome showed early signs of microvascular disease upon screening. In a study using urinalysis screening to detect microvascular disease, 1 in 5 adults with Prader-Willi ...
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with ...
A new PDUFA target action date of March 27, 2025 has been set for the application. The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ...
-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support ...
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq ...
Juliana Steffan's mother, April Steffan, created a YouTube video about Prader-Willi syndrome, a rare genetic disorder that causes a chronic feeling of hunger, among other physical, mental and ...
In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized cutting-edge findings on Prader-Willi syndrome (PWS), revealing how this complex ...
Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a ...
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with ...
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results